NAMSA Taps MedTech Veteran Scott Day to Steer Global Growth Strategy

TOLEDO, Ohio – April 20, 2026 – Global MedTech contract research organization (CRO) NAMSA has appointed Scott Day, a seasoned commercial leader with over two decades of experience, as its new Vice President of Clinical and Consulting Business Development. The move signals a decisive step to fortify its leadership team and capitalize on a period of significant growth, reinforcing the company's strategy to become the comprehensive, end-to-end development partner for medical device innovators worldwide.

Day’s appointment is effective immediately and comes as the MedTech CRO landscape becomes increasingly competitive and sophisticated. As device manufacturers face mounting regulatory pressures and the rapid evolution of technology, they are increasingly turning to full-service CROs that can guide them from initial concept to commercialization. NAMSA’s strategic hire underscores a deep understanding of this market shift.

A Strategic Move in a Competitive Arena

NAMSA's decision to bring in a leader of Day's caliber is not happening in a vacuum. The MedTech CRO market, valued in the tens of billions, is characterized by intense competition from major players like Parexel and PPD, and a broader industry trend toward consolidation. To maintain a competitive edge, CROs are racing to expand their service portfolios and global footprints.

This appointment is the latest in a series of aggressive strategic moves by NAMSA. Since partnering with the healthcare-focused private equity firm ARCHIMED in 2020, the company has completed 11 acquisitions. Recent notable acquisitions include the U.S. medical device testing operations of WuXi AppTec in early 2025 and select assets of Labcorp's early development medical device testing business in January 2026. These deals significantly expanded NAMSA's laboratory capacity and scientific expertise in critical areas like biocompatibility and preclinical testing, solidifying its position as a market leader.

By integrating these new assets, NAMSA has been building a comprehensive service offering designed to de-risk development and shorten time-to-market for its clients. The addition of a strategic commercial leader like Day is the logical next step, aimed at leveraging these expanded capabilities to drive growth in its clinical and consulting divisions.

"NAMSA continues to invest in the talent and capabilities that fuel our clinical research and consulting growth," said Brian Smith, Chief Executive Officer at NAMSA. "Scott's appointment reflects our commitment to being the partner of choice for MedTech companies navigating the full development lifecycle."

The MedTech Navigator: Expertise for Complex Challenges

Scott Day’s extensive background makes him uniquely suited for the role. His career is a blend of direct industry experience and CRO leadership, giving him a 360-degree view of the challenges facing medical device developers.

Most recently, as Vice President of Global Business Development at NovaBone, Day led global OEM and co-development partnerships. This role provided him with firsthand insight into the commercial strategies and partnership dynamics that drive success within a medical device company. Before that, he served as Senior Vice President and General Manager at Telos Partners, a CRO specializing in regulatory affairs and innovation. This experience managing CRO strategy and operations means he is intimately familiar with the service side of the industry.

This dual perspective is a powerful asset. Today’s MedTech innovators are not just looking for a vendor to run a test; they need a strategic partner who understands the intricate dance between regulatory compliance, clinical validation, and commercial viability. With increasingly complex regulations like the EU's Medical Device Regulation (MDR) and heightened FDA scrutiny, particularly around AI-enabled and connected devices, expert navigation is more critical than ever.

Ryan Carpentier, Chief Commercial Officer at NAMSA, highlighted this unique value. "Scott's deep commercial background in MedTech means he understands the challenges our sponsors face every day, from navigating complex regulatory pathways to getting devices to market faster," Carpentier commented. "That perspective, combined with his experience leading a CRO and building high-performing commercial teams, will be a real asset as we continue growing our clinical and consulting business globally."

Fueling Growth with Integrated End-to-End Services

The appointment and Day’s specific title—Vice President, Clinical and Consulting Business Development—speak volumes about the industry's evolution. The traditional CRO model, with its siloed services for preclinical testing, clinical trials, and regulatory consulting, is becoming obsolete. The market now demands an integrated approach where all aspects of the development lifecycle are managed cohesively.

NAMSA has positioned itself at the forefront of this trend, championing an "end-to-end" service model. Day's role is to bridge the gap between the company's vast scientific and clinical capabilities and the commercial and strategic needs of its clients. He will be responsible for ensuring that NAMSA’s more than 3,000 clients, ranging from emerging startups to established global manufacturers, can fully leverage the company's integrated suite of services.

This strategy directly addresses the pressures of the modern MedTech market. With investors prioritizing companies with clear de-risking and commercialization plans, the ability to partner with a single CRO that can provide a seamless path through development is a significant advantage. It reduces administrative burden, improves communication, and ultimately accelerates the delivery of innovative medical technologies to patients.

Day joins NAMSA at a pivotal moment, tasked with harnessing the momentum from its recent acquisitions and translating its expanded capabilities into new client partnerships and deeper market penetration. His focus will be on demonstrating how NAMSA's comprehensive model offers a more efficient and cost-effective pathway through the complex product development lifecycle, solidifying the company's claim as the MedTech industry's partner of choice.